Global X Management Co. LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.8% during the second quarter, Holdings Channel reports. The firm owned 1,205 shares of the biopharmaceutical company’s stock after buying an additional 367 shares during the period. Global X Management Co. LLC’s holdings in Regeneron Pharmaceuticals were worth $592,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the period. Janus Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock valued at $510,406,000 after buying an additional 486,119 shares during the period. Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the period. Clearbridge Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock valued at $267,480,000 after buying an additional 245,531 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Regeneron Pharmaceuticals by 36.8% in the first quarter. Bank of New York Mellon Corp now owns 881,867 shares of the biopharmaceutical company’s stock valued at $341,733,000 after buying an additional 237,157 shares during the period. 67.16% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals, Inc. (REGN) opened at 468.54 on Thursday. The company’s 50 day moving average is $492.11 and its 200-day moving average is $429.80. The stock has a market cap of $49.68 billion, a PE ratio of 47.00 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm’s revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the business earned $2.82 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Global X Management Co. LLC Has $592,000 Position in Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/17/global-x-management-co-llc-has-592000-position-in-regeneron-pharmaceuticals-inc-regn.html.

REGN has been the subject of several analyst reports. Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $375.00 to $484.00 in a research report on Friday, May 5th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 price target for the company. in a research report on Monday, May 1st. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Piper Jaffray Companies raised their price target on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $488.23.

In other news, Chairman P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now owns 414,156 shares in the company, valued at $189,741,429.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Sanofi bought 136,050 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was bought at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 56,922 shares of company stock worth $27,383,105. 10.40% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.